Status:
ACTIVE_NOT_RECRUITING
EUS-guided PORtal Vein Sampling for Circulating Tumor Cells in Pancreatic Cancer Patients
Lead Sponsor:
IRCCS San Raffaele
Conditions:
Pancreatic Cancer
Pancreatic Adenocarcinoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The study aims at evaluating the feasibility and safety of EUS-guided Portal Circulation sampling for isolation, enumeration and profiling od Circulating Tumor Cells (CTC) in Pancreatic Cancer patient...
Detailed Description
Prognostic stratification of patients with Pancreatic Ductal Adenocarcinoma (PDAC) is still suboptimal, relying only on imaging studies and Carbohydrate Antigen 19.9 to drive important treatment decis...
Eligibility Criteria
Inclusion
- patient with a pancreatic solid lesion undergoing EUS with a rapid on-site confirmation of a pancreatic ductal adenocarcinoma
- patients primarily followed within San Raffaele Institute
Exclusion
- history of active non-pancreatic cancer
- coagulopathy (INR \> 1.5; platelets \< 70.000/ul) or use of non-withdrawable anticoagulant or antiplatelet
- known history or endosonographic signs of portal hypertension
- extensive invasion of portal vein precluding needle maneuvers
- pregnancy and breastfeeding
Key Trial Info
Start Date :
May 17 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2027
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT05247164
Start Date
May 17 2022
End Date
March 1 2027
Last Update
May 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCCS San Raffaele Scientific Institute
Milan, Italy, 20132